3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1/2
3
Phase 1
3
Phase 3
2
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Ovarian Neoplasms
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
BRCA or HRR+ Mutated Ovarian Cancer Patients
1
Interventions
Medroxyprogesterone Acetate
3
semaglutide
1
pazopanib
1
palbociclib
1
olaparib
1
lenvatinib
1
fluciclovine F-18
1
ferrous gluconate
1
dostarlimab
1
Watchful Waiting
1
Sunitinib
1
Specimen Handling
1
Resistance Training
1
Progestins
1
Observation
1
Nutrition Assessment
1
Metformin
1
Megestrol Acetate
1
Magnetic Resonance Spectroscopy
1
LY 353381
1
Indocyanine Green
1
Hysteroscopy
1
High-Energy Shock Waves
1
Estrogen Replacement Therapy
1
Biomarkers
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Endometrial Neoplasms
×
olaparib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled